Bristol-Myers Squibb

Bristol-Myers teams with BioMotiv to build and buy biotechs
Fierce Biotech
Wed, 09/4/19 - 10:25 am
Bristol-Myers Squibb
BioMotiv
M&A
biotech
ESC: New Pfizer, BMS real-world data could boost Eliquis in Europe
Fierce Pharma
Mon, 09/2/19 - 12:17 pm
Pfizer
Bristol-Myers Squibb
Eliquis
Warfarin
bloodthinners
Europe
ESC
European Society of Cardiology
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Endpoints
Wed, 08/28/19 - 12:38 pm
Bristol-Myers Squibb
AbbVie
Empliciti
Celgene
Europe
relapsed or refractory multiple myeloma
Six burning Otezla questions
EP Vantage
Tue, 08/27/19 - 10:53 pm
Celgene
Otezla
Amgen
drug pricing
FTC
Tyk2
Bristol-Myers Squibb
Bristol-Myers opens up the Phase 0 pathway in testing its new cancer therapies, following in Celgene’s footsteps
Endpoints
Tue, 08/27/19 - 09:55 am
Bristol-Myers Squibb
Celgene
Presage Biosciences
Phase 0 testing
drug development
Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger
Stat
Mon, 08/26/19 - 10:24 am
Amgen
Otezla
Celgene
M&A
Bristol-Myers Squibb
psoriasis
What happened a year ago this week in biopharma? August 12-18, 2018
Mon, 08/19/19 - 11:04 am
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
What happened a year ago this week in biopharma? August 12-18, 2018
CP WIre
Sun, 08/18/19 - 04:30 pm
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
Celgene wins approval for drug key to Bristol buyout
Biopharma Dive
Fri, 08/16/19 - 01:06 pm
Celgene
FDA
Inrebic
myelofibrosis
M&A
Bristol-Myers Squibb
Which pharmas grew most in Q2? AstraZeneca, Merck and BMS, for 3
Fierce Pharma
Thu, 08/15/19 - 10:42 am
earnings
AstraZeneca
Merck
Bristol-Myers Squibb
Celgene Continues Growing While Waiting for its Acquisition to Close
Motley Fool
Wed, 08/7/19 - 10:55 am
Celgene
earnings
M&A
Bristol-Myers Squibb
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
Yahoo/Motley Fool
Sun, 08/4/19 - 01:02 pm
Merck
Keytruda
AbbVie
Humira
Pfizer
Bristol-Myers Squibb
Eliquis
JNJ
Imbruvica
Wiping its slate ahead of BMS buy, Celgene to pay $117M in Revlimid antitrust settlements
Fierce Pharma
Fri, 08/2/19 - 12:28 am
Celgene
Bristol-Myers Squibb
antitrust
Anti-PD-1 Drug Opdivo Significantly Improves Five Year Survival In Advanced Cancers
Forbes
Wed, 07/31/19 - 08:57 am
advanced cancer
Opdivo
Bristol-Myers Squibb
advanced melanoma
Celgene Offers Beat-And-Raise As Bristol Merger Looms Closer
Investors Business Daily
Wed, 07/31/19 - 08:50 am
Celgene
earnings
M&A
Bristol-Myers Squibb
Sales gap grows between rival Merck, Bristol cancer therapies
Biopharma Dive
Tue, 07/30/19 - 11:33 am
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
cancer
Bristol's Celgene buyout 'more important' given drug pricing pressure, CEO says
Fierce Pharma
Thu, 07/25/19 - 10:38 pm
Bristol-Myers Squibb
Celgene
M&A
drug pricing
Giovanni Caforio
Bristol-Myers’ Rosy Outlook Trumps Trial Setback as Stock Gains
Yahoo/Bloomberg
Thu, 07/25/19 - 10:52 am
earnings
Bristol-Myers Squibb
Opdivo
Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck
Xconomy
Wed, 07/24/19 - 10:20 pm
Bristol-Myers Squibb
Merck
Keytruda
Opdivo
non-squamous
non-squamous non-small cell lung cancer
Biogen, Celgene, Bristol-Myers and AbbVie report earnings this week: Here’s what to expect
Marketwatch
Mon, 07/22/19 - 10:15 am
Celgene
Biogen
AbbVie
Bristol-Myers Squibb
earnings

Pages